Open AccessThe endolysin of the Acinetobacter baumannii phage vB_AbaP_D2 shows broad antibacterial activity
Author(s) -
Yuan Yuyu,
Li Xiaoyu,
Wang Lili,
Li Gen,
Cong Cong,
Li Ruihua,
Cui Huijing,
Murtaza Bilal,
Xu Yongping
Publication year - 2021
Publication title -
microbial biotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.287
H-Index - 74
ISSN - 1751-7915
DOI - 10.1111/1751-7915.13594
Subject(s) - microbiology and biotechnology , acinetobacter baumannii , lysin , bacteriophage , pseudomonas aeruginosa , biology , antimicrobial , acinetobacter , multiple drug resistance , staphylococcus aureus , bacteria , antibiotic resistance , enterococcus faecium , antibiotics , escherichia coli , biochemistry , genetics , gene
Summary The emergence and rapid spread of multidrug‐resistant bacteria has induced intense research for novel therapeutic approaches. In this study, the Acinetobacter baumannii bacteriophage D2 (vB_AbaP_D2) was isolated, characterized and sequenced. The endolysin of bacteriophage D2, namely Abtn‐4, contains an amphipathic helix and was found to have activity against multidrug‐resistant Gram‐negative strains. By more than 3 log units, A. baumannii were killed by Abtn‐4 (5 µM) in 2 h. In absence of outer membrane permeabilizers, Abtn‐4 exhibited broad antimicrobial activity against several Gram‐positive and Gram‐negative bacteria, such as Staphylococcus aureus , Pseudomonas aeruginosa , Klebsiella pneumonia , Enterococcus and Salmonella . Furthermore, Abtn‐4 had the ability to reduce biofilm formation. Interestingly, Abtn‐4 showed antimicrobial activity against phage‐resistant bacterial mutants. Based on these results, endolysin Abtn‐4 may be a promising candidate therapeutic agent for multidrug‐resistant bacterial infections.